TY - JOUR
T1 - Influenza vaccination in orthotopic liver transplant recipients
T2 - Absence of post administration ALT elevation
AU - Lawal, Adeyemi
AU - Basler, Chris
AU - Branch, Andrea
AU - Gutierrez, Julio
AU - Schwartz, Myron
AU - Schiano, Thomas D.
PY - 2004/11
Y1 - 2004/11
N2 - Influenza vaccination has reduced life-threatening complications from influenza virus infection in adult liver transplant recipients. We evaluated changes in aminotransferase level and immunogenicity of influenza vaccination in liver transplant recipients. Fifty-one liver transplant recipients were administered a standard dose of the 2002-2003 inactivated trivalent influenza vaccine. ALT values were measured at baseline, 1 week and 4-6 weeks postvaccination. Antibody responses to each component of the vaccine were measured at baseline and after 4-6 weeks by a hemagglutination inhibition (HAI) assay. Response was defined as an HAI titer ≥ 1: 40 and/or a 4-fold increase in antibody titers from baseline. An ALT elevation was defined as a rise of ≥ 50% from baseline. There was no difference in the median rise in ALT value between seroconverters and nonseroconverters. A significant number of recipients developed potentially protective antibody titers (p-value < 0.0001). At less than 4 months post transplantation, 1/7 (14%), at 4-12 months, 6/9 (67%), and after 12 months, 30/35 (86%) subjects responded to the H1 strain. Of 51 recipients, one HCV (-) recipients vaccinated within 3 months of transplantation developed acute cellular rejection. Influenza virus vaccination is not associated with allograft rejection or ALT flares in liver transplant recipients.
AB - Influenza vaccination has reduced life-threatening complications from influenza virus infection in adult liver transplant recipients. We evaluated changes in aminotransferase level and immunogenicity of influenza vaccination in liver transplant recipients. Fifty-one liver transplant recipients were administered a standard dose of the 2002-2003 inactivated trivalent influenza vaccine. ALT values were measured at baseline, 1 week and 4-6 weeks postvaccination. Antibody responses to each component of the vaccine were measured at baseline and after 4-6 weeks by a hemagglutination inhibition (HAI) assay. Response was defined as an HAI titer ≥ 1: 40 and/or a 4-fold increase in antibody titers from baseline. An ALT elevation was defined as a rise of ≥ 50% from baseline. There was no difference in the median rise in ALT value between seroconverters and nonseroconverters. A significant number of recipients developed potentially protective antibody titers (p-value < 0.0001). At less than 4 months post transplantation, 1/7 (14%), at 4-12 months, 6/9 (67%), and after 12 months, 30/35 (86%) subjects responded to the H1 strain. Of 51 recipients, one HCV (-) recipients vaccinated within 3 months of transplantation developed acute cellular rejection. Influenza virus vaccination is not associated with allograft rejection or ALT flares in liver transplant recipients.
KW - Hepatitis C virus
KW - Influenza vaccination
KW - Liver transplantation
UR - http://www.scopus.com/inward/record.url?scp=7244250306&partnerID=8YFLogxK
U2 - 10.1111/j.1600-6143.2004.00564.x
DO - 10.1111/j.1600-6143.2004.00564.x
M3 - Article
C2 - 15476480
AN - SCOPUS:7244250306
SN - 1600-6135
VL - 4
SP - 1805
EP - 1809
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 11
ER -